| Derek Hunt, | |
|
709 Sugar Bend Cir Sw, Madison, AL 35756-5311 | |
| (904) 233-7038 | |
| Not Available |
| Full Name | Derek Hunt |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 8 Years |
| Location | 709 Sugar Bend Cir Sw, Madison, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740642180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 207PE0004X (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Merit Health Wesley | Hattiesburg, MS | Hospital |
| Southwest Ms Regional Medical Center | Mccomb, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Mississippi Regional Medical Center | 5193633907 | 65 |
| Hattiesburg Hb Medical Services Llc | 6507220167 | 9 |
News Archive
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer's disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.
A study by researchers at Mayo Clinic in Arizona published in the the Journal of Clinical Investigation has found that obesity is not only implicated in chronic diseases such as diabetes, but also in sudden-onset diseases such as pancreatitis.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 8 days ago
| Entity Name | Southwest Mississippi Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982174488 PECOS PAC ID: 5193633907 Enrollment ID: O20080512000004 |
News Archive
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer's disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.
A study by researchers at Mayo Clinic in Arizona published in the the Journal of Clinical Investigation has found that obesity is not only implicated in chronic diseases such as diabetes, but also in sudden-onset diseases such as pancreatitis.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 8 days ago
| Entity Name | App Of Mississippi Ed Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730687740 PECOS PAC ID: 3971865858 Enrollment ID: O20180313002534 |
News Archive
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer's disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.
A study by researchers at Mayo Clinic in Arizona published in the the Journal of Clinical Investigation has found that obesity is not only implicated in chronic diseases such as diabetes, but also in sudden-onset diseases such as pancreatitis.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 8 days ago
| Entity Name | Relias Emergency Medicine Specialists Of Mccomb, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477195972 PECOS PAC ID: 7517391121 Enrollment ID: O20200107000381 |
News Archive
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer's disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.
A study by researchers at Mayo Clinic in Arizona published in the the Journal of Clinical Investigation has found that obesity is not only implicated in chronic diseases such as diabetes, but also in sudden-onset diseases such as pancreatitis.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 8 days ago
| Entity Name | Hattiesburg Hb Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699456376 PECOS PAC ID: 6507220167 Enrollment ID: O20230914003005 |
News Archive
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer's disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.
A study by researchers at Mayo Clinic in Arizona published in the the Journal of Clinical Investigation has found that obesity is not only implicated in chronic diseases such as diabetes, but also in sudden-onset diseases such as pancreatitis.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Derek Hunt, 709 Sugar Bend Cir Sw, Madison, AL 35756-5311 Ph: (904) 233-7038 | Derek Hunt, 709 Sugar Bend Cir Sw, Madison, AL 35756-5311 Ph: (904) 233-7038 |
News Archive
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer's disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.
A study by researchers at Mayo Clinic in Arizona published in the the Journal of Clinical Investigation has found that obesity is not only implicated in chronic diseases such as diabetes, but also in sudden-onset diseases such as pancreatitis.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
› Verified 8 days ago
Dr. Milton A Padgett, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 165 Chestnut Dr Ste D, Madison, AL 35758 Phone: 256-325-7666 Fax: 256-325-7667 | |
Dr. Ehtisham R. Khan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8371 Highway 72 W, Suite 104, Madison, AL 35758 Phone: 256-265-5970 Fax: 256-817-5956 | |
Aletha Lakay Edison, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7583 Wall Triana Hwy, Madison, AL 35757 Phone: 256-547-6119 Fax: 256-546-2981 | |
Dr. Herbert C Frith Ii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8375 Highway 72 W, Madison, AL 35758 Phone: 256-265-5051 | |
Hannah Eason Bates, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 107 Waterford Cir, Madison, AL 35758 Phone: 256-517-3011 | |
Verne H Webster, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8045 Highway 72 W, Suite 100, Madison, AL 35758 Phone: 256-837-2271 Fax: 256-837-2910 |